期刊文献+

溴己新联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床研究 被引量:1

Clinical study on bromhexine combined with tiotropium bromide in treatment of chronic obstructive pulmonary disease in stable stage
收藏 分享 导出
摘要 目的探讨盐酸溴己新片联合噻托溴铵粉雾剂治疗慢性阻塞性肺疾病稳定期的临床疗效。方法选取2018年2月—2019年2月在新乡市中心医院治疗的100例慢性阻塞性肺疾病稳定期患者为研究对象,将所有患者随机分为对照组和治疗组,每组各50例。对照组患者给予噻托溴铵粉雾剂,1粒/次,1次/d;治疗组在对照组基础上口服盐酸溴己新片,2片/次,3次/d。两组患者持续治疗3个月。观察两组的临床疗效,比较两组的mMRC评分、慢性阻塞性肺病评估测试量表(CAT)评分、6 min步行距离(6 MWT)、肺功能、血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为76.00%、92.00%,两组比较差异有统计学意义(P<0.05)。治疗后,两组mMRC评分和CAT评分显著降低,6MWT显著升高,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组m MRC评分、CAT评分、6 MWT明显优于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组第1秒用力呼气容积(FEV1)/用力肺活量(FVC)、FEV1、FVC显著升高,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组肺功能指标明显高于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-4(IL-4)水平显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者血清炎性因子水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论盐酸溴己新片联合噻托溴铵粉雾剂治疗慢性阻塞性肺疾病稳定期具有较好临床疗效,能改善肺功能和生活质量,降低血清炎性因子水平,具有一定的临床推广应用价值。 Objective To investigate the effect of Bromhexine Hydrochloride Tablets combined with Tiotropium Bromide Powder for inhalation in treatment of chronic obstructive pulmonary disease in stable stage.Methods Patients(100 cases)with chronic obstructive pulmonary disease in stable stage in Xinxiang Central Hospital from February 2018 to February 2019 were randomly divided into control and treatment groups,and each group had 50 cases.Patients in the control group were given Tiotropium Bromide Powder for inhalation,1 grains/time,once daily.Patients in the treatment group were po administered with Bromhexine Hydrochloride Tablets on the basis of the control group,2 tablets/time,three times daily.Patients in two groups were treated for 3 months.After treatment,the clinical efficacies were evaluated,and mM RC scores,CAT scores,6 MWT,pulmonary function,and serum levels of inflammatory factors in two groups were compared.Results After treatment,the clinical efficacies in the control and treatment groups were 76.00%and 92.00%,respectively,and there was difference between two groups(P<0.05).After treatment,mM RC scores and CAT scores in two groups were significantly decreased,but 6 MWT in two groups were significantly increased,and the difference was statistically significant in the same group(P<0.05).And the observational indexes in the treatment group were significantly better than those in the control group,with significant difference between two groups(P<0.05).After treatment,FEV1/FVC,FEV1,and FVC in two groups were significantly increased,and the difference was statistically significant in the same group(P<0.05).And the pulmonary function indexes in the treatment group were significantly higher than those in the control group,with significant difference between two groups(P<0.05).After treatment,the levels of CRP,IL-4,and IL-6 in two groups were significantly decreased,and the difference was statistically significant in the same group(P<0.05).And the serum levels of inflammatory factors in the treatment group were signifi
作者 李小丽 夏玉红 陈亚飞 张瑞 LI Xiao-li;XIA Yu-hong;CHEN Ya-fei;ZHANG Rui(Department of Respiratory Medicine,Xinxiang Central Hospital,Xinxiang 453000,China)
出处 《现代药物与临床》 CAS 2020年第1期105-108,共4页 Drugs & Clinic
关键词 盐酸溴己新片 噻托溴铵粉雾剂 慢性阻塞性肺疾病稳定期 mMRC评分 肺功能 炎性因子 Bromhexine Hydrochloride Tablets Tiotropium Bromide Powder for inhalation chronic obstructive pulmonary disease in stable stage mMRC score pulmonary function inflammatory factor
  • 相关文献

参考文献16

二级参考文献128

共引文献1612

引证文献1

论文智能改写系统
维普数据出版直通车
投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈